Back to Search
Start Over
Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study
- Source :
- Scientific Reports, Scientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
- Publication Year :
- 2017
-
Abstract
- Data on the association between aspirin and statin use and Pancreatic Ductal AdenoCarcinoma (PDAC) risk are conflicting. These drugs are often co-prescribed, but no studies evaluated the potential combined or confounding effect of the two at the same time. We aimed to investigate the association between aspirin and statin exclusive and combined use and PDAC occurrence. Data on environmental factors, family and medical history were screened in a case-control study. PDAC cases were matched to controls for age and gender. Power calculation performed ahead. Odds ratios (OR) and 95% confidence intervals(CI) were obtained from multivariable logistic regression analysis. In 408 PDAC patients and 816 matched controls, overall statin (OR 0.61; 95%CI,0.43–0.88), but not aspirin use was associated to reduced PDAC risk. Compared to non-users, exclusive statin (OR 0.51; 95%CI,0.32–0.80) and exclusive aspirin users (OR 0.64; 95%CI,0.40–1.01) had reduced PDAC risk. Concomitant statin and aspirin use did not further reduce the risk compared with statin use alone and no interaction was evident. Statin protective association was dose-dependent, and consistent in most subgroups, being stronger in smokers, elderly, obese and non-diabetic patients. The present study suggests that statin use is associated to reduced PDAC risk, supporting a chemopreventive action of statins on PDAC.
- Subjects :
- Oncology
Male
medicine.medical_specialty
Statin
endocrine system diseases
medicine.drug_class
lcsh:Medicine
Article
03 medical and health sciences
0302 clinical medicine
Pharmacotherapy
Drug Therapy
Risk Factors
Pancreatic cancer
Internal medicine
medicine
Humans
lcsh:Science
Life Style
Aged
Aspirin
Multidisciplinary
business.industry
lcsh:R
Case-control study
Odds ratio
medicine.disease
Confidence interval
digestive system diseases
Surgery
Pancreatic Neoplasms
030220 oncology & carcinogenesis
Concomitant
Case-Control Studies
Combination
lcsh:Q
030211 gastroenterology & hepatology
Drug Therapy, Combination
Female
Hydroxymethylglutaryl-CoA Reductase Inhibitors
business
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Scientific Reports, Scientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
- Accession number :
- edsair.doi.dedup.....d354bd6759cddc38435713482b565219